

- 2) 吉岡祐亮, 小坂展慶, 加藤尚志, 落谷孝広.  
鉄欠乏により発現誘導される miR-210 の  
標的遺伝子の同定と機能解析. (Iron  
deficiency-inducible miR-210 suppress  
iron homeostasis related proteins.) 第 69  
回日本癌学会, ポスター, 大阪国際会議場,  
2010 年 9 月 22~24 日
- 3) 吉岡祐亮, 杉浦圭一, 小坂展慶, 山本雄介,  
宮崎洋, 小松則夫, 落谷孝広, 加藤尚志.  
エリスロポエチンにより誘導される  
miR-188 と miR-362 のマウス赤血球造血  
における発現. (Erythropoietin-Induced  
Expression of miR-188 and miR-362 in  
Primary Murine Erythrocytes.) 第 72 回  
日本血液学会学術集会, 一般口演 OS-3-14,  
セッション 67「赤血球造血」, 横浜パシフ  
ィコ, 2010 年 9 月 24 日
- 4) 吉岡祐亮, 小坂展慶, 加藤尚志, 落谷孝広.  
鉄代謝の fine-tuner としての miR-210 の  
意義. 第 2 回日本 RNAi 学会, グランドブ  
リンスホテル広島, 2010 年 8 月 27~28  
日

G. 知的財産権の出願・登録状況

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
菅野康吉	家族性大腸腺腫症	幕内雅敏 菅野健太郎	今日の消化器疾患治療指針	医学書院	東京	2010	506-508
菅野康吉	遺伝相談（遺伝カウンセリング）	斉藤裕輔 田中信治 渡邊聡明	大腸疾患診療のStrategy	株式会社日本メデイカルセンター	東京	2010	441-445
菅野康吉	腫瘍マーカーNCC-ST-439	家入蒼生夫	広範囲血液・尿科学検査免疫学的検査 [第7版]	株式会社日本臨床社	大阪	2010	726-728
菅野康吉	がん遺伝子解析から遺伝子診断（臨床応用）へのニーズと問題点	菅原隆	体外診断用医薬品の開発と承認申請～医療現場のニーズにマッチした開発戦略とは何か～	株式会社技術情報協会	東京	2010	278-285
菅野康吉	BRCA1/2遺伝子検査	高久史麿 黒川清 春日雅人 北村聖	臨床検査データブック2011-2012	医学書院	東京	2011	671-672

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hudson TJ Yoshida T, et al	International network of cancer genome projects	Nature	464: 7291	993-998	2010
Sai K., Yoshida T, et al	Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients	Cancer Chemother. Pharmacol	66:1	95-105	2010

Sato Y, Sakamoto H, <u>Yoshida T</u> , Ohtaki M.	Detection of inappropriate samples in association studies by an IBS-based method considering linkage disequilibrium between genetic markers.	Jounal Human Genetics	55	436-440	2010
<u>Yoshida T</u> , Ono H, Kuchiba A, Saeki N, Sakamoto H.	Genome-wide germline analyses on cancer susceptibility and GeMDBJ database: gastric cancer as an example	Cancer Science	101: 7	1582-1589	2010
Siew-Kee L., <u>Yoshida T</u> , et al	Genome-wide association study of pancreatic cancer in Japanese population.	PLos One	5:7	e11824-1-6	2010
Sugiyama E., <u>Yoshida T</u> , et al	Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: Impact of genetic polymorphisms.	Clinical Pharmacokinetics	49:8	549-558	2010
Sai K., <u>Yoshida T</u> , et al	Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.	Br J Clin Pharmacol	70:2	222-233	2010
Sangrajrang S., <u>Yoshida T</u> , et al	Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk a case-control study in Thai women.	Breast Cancer Res Treat.	123	885-893	2010
Sato Y., <u>Yoshida T</u> , et al	Biostatistic tools in pharmacogenomics--advances, challenges, potential.	Curr Pharm Des	16	2232-2240	2010
Saeki N., <u>Yoshida T</u> , et al	Prostate Stem Cell Antigen: A Jekyll and Hyde Molecule?	Clin Cancer Res	16	3533-3538	2010.

Sato Y., Yoshida T, et al	Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.	J Thorac Oncol.	6	132-138	2011
Totoki Y., Yoshida T, et al	High-resolution characterization of a hepatocellular carcinoma genome.	Nat Genet	43	464-469	2011
Saeki N., Yoshida T, et al	A functional SNP in MUC1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer	Gastroenterology	140	892-902	2011
Katori N., Yoshida T, et al	Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients	to the Journal of Pharmaceutical Sciences			in press.
Que N, Noguchi T, Anami K, Sentani K, Sakamoto N, Uraoka N, Wakamatsu Y, Sasaki H and Yasui W	Serum concentration and expression of Reg IV in patients with esophageal cancer: age-related elevation of serum Reg IV concentration	Oncol Lett	2	235-239	2011
Sentani K, Que N, Sakamoto N, Anami K, Naito Y, Aoyagi K, Sasaki H and Yasui W	Up-regulation of connexin 30 in intestinal phenotype gastric cancer and its reduction during tumor progression	Pathobiology	77	241-248	2010
Qui W, Wang X, Leibowitz, Liu H, Barker N, Okada H, Que N, Yasui W, Clevers H, Schoen RE, Yu J and Zhang L	Chemoprevention by nonsteroidal anti-inflammatory drug eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis	Proc Natl Acad Sci USA	107	20027-20032	2010
Matsuda M, Sentani K, Noguchi T, Hinoi T, Okajima M, Matsusaki K, Sakamoto N, Anami K, Naito Y, Que N and Yasui W	Immunohistochemical analysis of colorectal cancer with gastric phenotype: Ectopic expression of claudin-18 is associated with poor prognosis	Pathol Int	60	673-680	2010

Takakura Y, Hinoi T, <u>Oue N</u> , Sasada T, Kawaguchi Y, Okajima M, Akyol A, Fearon ER, Yasui W and Ohdan H	CDX2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium	Cancer Res	70	6767-6778	2010
Tanaka M, Kitadai Y, Kodama M, Shinagawa K, Sumida T, Tanaka S, <u>Oue N</u> , Yasui W and Chayama K	Potential role for vascular endothelial growth factor-D as an autocrine factor for human gastric carcinoma cells	Cancer Sci	101	2121-2127	2010
Anami K, <u>Oue N</u> , Noguchi T, Sakamoto N, Sentani K, Hayashi T, Hinoi T, Okajima M, Graff JM and Yasui W	Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in gastric cancer with intestinal phenotype	J Pathol	221	275-284	2010
Sentani K, <u>Oue N</u> , Noguchi T, Sakamoto N, Matsusaki K and Yasui W	Immunostaining of gastric cancer with neuroendocrine differentiation: Reg IV-positive neuroendocrine cells are associated with gastrin, serotonin, pancreatic polypeptide and somatostatin	Pathol Int	60	291-297	2010
Sakamoto N, <u>Oue N</u> , Noguchi T, Sentani K, Anami K, Sanada Y, Yoshida K and Yasui W	Serial analysis of gene expression of esophageal squamous cell carcinoma: ADAMTS16 is up-regulated in esophageal squamous cell carcinoma	Cancer Sci	101	1038-1044	2010
Yamamoto H, <u>Oue N</u> , Sato A, Hasegawa Y, Yamamoto H, Matsubara A, Yasui W and Kikuchi A	Wnt5a signaling is involved in aggressiveness of prostate cancer and expression of metalloproteinase	Oncogene	29	2036-2046	2010
Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, <u>Oue N</u> , Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA and Croce CM	Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis	Lancet Oncol	11	136-146	2010
Seko N, <u>Oue N</u> , Noguchi T, Sentani K, Sakamoto N, Hinoi T, Okajima M and Yasui W	Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer	Exp Ther Med	1	73-78	2010

Miyake M, <u>Sugano K</u> , Sugino H, Imai K, Matsumoto E, Maeda K, Fukuzono S, Ichikawa H, Kawashima K, Hirabayashi K, Kodama T, Fujimoto H, Kakizoe T, Kanai Y, Fujimoto, K, Hirao Y.	Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.	Canser Sci.	101	250-58	2010
Miyake M, Ishii M, Koyama N, Kawashima K, Kodama T, Anai S, Fujimoto K, Hirao Y, <u>Sugano K</u> .	1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-dimethylamino-butylamino)-pyridin-2-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regulation of p27/Kip1 and G1/G0 Arrest.	J Pharmacol Exp Ther.	332	795-802	2010
Koyamatsu Y, Sakamoto M, Miyake K, Muroya T, <u>Sugano K</u> , Nakao Y, Yokoyama M, Iwasaka T.	Gene expression profiles and microsatellite instability in uterine corpus endometrioid adenocarcinoma.	J Obstet Gynaecol Res.	36	336-343	2010
Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, <u>Sugano K</u> , Kawashima K, Laird PW, Jones PA, Liang G.	Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue.	Cancer Res	70	8169-8178	2010
Ito T, Williams-Nate Y, Iwai M, Tsuboi M, Hagiwara M, Ito A, Sakurai-Yageta M, and <u>Murakami Y</u> .	Transcriptional regulation of the CADM1 gene by retinoic acid during the neural differentiation of murine embryonal carcinoma P19 cells.	Genes to Cells,	in press	in press	2011
Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F, and <u>Murakami Y</u> .	Aberrant expression of tumor suppressors, CADM1 and 4.1B, in invasive lesions of primary breast cancer.	Breast Cancer	in press	in press	2011

Hagiya M, Furuno T, Hosokawa Y, Iino T, Ito T, Inoue T, Kakanishi M, <u>Murakami Y</u> and Ito A.	Enhanced Nerve-Mast Cell Interaction by a Neuronal Short Isoform of Cell Adhesion Molecule-1, CADM1.	J Immunology		in press	2011
Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y, and <u>Murakami Y</u> .	Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma.	Int J Cancer	in press	in press	2011
Mimae T, Tsuta K, Takahashi F, Yoshida A, Kondo T, <u>Murakami Y</u> , Okada M, Takeuchi M, Asamura H, Tsuda H.	Steroid Receptor Expression in Thymomas and Thymic Carcinomas.	Cancer	108	in press	2011
Hosokawa Y, Hagiya M, Iino T, <u>Murakami Y</u> , Ito A.	Non-contact estimation of intercellular breaking force using femtosecond laser impulse quantified by atomic force microscopy.	Proc Natl Acad Sci	285	1777-1782	2011
Masuda M, Maruyama T, Ohta T, Ito A, Hayashi T, Tsukasaki K, Kamihira S, Yamaoka S, Hoshino H, Yoshida T, Watanabe T, Stanbridge EJ and <u>Murakami Y</u>	CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I (HTLV-I) transformed cells and adult T-cell leukemia (ATL) cells.	Journal of Biological Chemistry	101	15511-15522	2010
K. Narumi, A. Kondoh, T. Udagawa, H. Hara, N. Goto, Y. Ikarashi, S. Ohnami, T. Okada, M. Yamagishi, T. Yoshida and <u>K. Aoki</u> .	Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer	Cancer Sci.	70	1686-1694,	2010

M. Shitashige, R. Satow, T. Jigami, K. Aoki, K. Honda, T. Shibata, M. Ono, S. Hirohashi and T Yamada.	Traf2- and Nck-interacting kinase TNIK is essential for Wnt signaling and colorectal cancer growth.	Cancer Res		5024-5033	2010
K. Aoki and K. Narumi.	Development of interferon- $\beta$ gene therapy against pancreatic cancer. In: Cancer Gene Therapy ed. by Tagawa M. Research Signpost	Kerala, India		175-193.	2010
K. Narumi, T. Udagawa, A. Kobayashi, H. Hara, A. Kondoh, N. Goto, Y. Ikarashi, S. Ohnami, F. Takeshita, T. Ochiya, T. Okada, M. Yamagishi, T. Yoshida and K. Aoki	In vivo interferon- $\beta$ gene transfer enhances antitumor immunity after autologous hematopoietic stem cell transplantation	Gene Ther.			(in press)
Kaneda, Y.	A non-replicating oncolytic vectors as a novel therapeutic tool against cancer.	BMB Reports	In press	773-780	2010
Matsuda, M., Nimura, K., Shimbo, T., Hamasaki, T., Yamamoto, T., Matsumura, A. and Kaneda, Y.	Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.	J. Neuro-Oncology		In press	2011



